Chemotherapy may suppress breast cancer risk in Hodgkin's survivors

July 01, 2003

Women treated with radiation therapy for Hodgkin's disease are at a strongly increased risk of breast cancer. Now, a new study suggests that this risk for breast cancer increases with increasing radiation dose. However, adding chemotherapy to radiation is associated with a reduction in this risk, possibly by inducing premature menopause. The findings appear in the July 2 issue of the Journal of the National Cancer Institute.

Flora E. van Leeuwen, Ph.D., of the Netherlands Cancer Institute, and her colleagues examined radiation dose, chemotherapy with alkylating agents, and reproductive factors in women diagnosed with Hodgkin's disease before age 41. They compared these factors in 48 women who had developed breast cancer 5 or more years after their Hodgkin's disease diagnosis and 175 matched control women who did not develop breast cancer.

Among patients treated with radiation alone, the risk of breast cancer increased with increasing radiation dose. Patients who received 38.5 Gy or more of radiation had 4.5 times the risk of breast cancer than patients who received less than 4 Gy. This dose-dependent increase in breast cancer risk was not seen in patients who received both radiation and chemotherapy. Patients who were treated with both chemotherapy and radiation therapy had a 61% lower risk of breast cancer than patients treated with radiation therapy alone.

The authors suggest that the decrease in risk of breast cancer in patients treated with radiation therapy and chemotherapy may be associated with chemotherapy-induced premature menopause. They found that 69% of patients treated with chemotherapy plus radiation reached menopause before the age of 41, compared with only 9% of patients treated with radiation alone. Reaching menopause before age 36 was associated with a 94% reduction in risk of breast cancer, compared with reaching menopause after age 45.

These findings suggest that ovarian hormones play a role in promoting tumor growth after radiation has initiated the process, potentially explaining why women who are exposed to radiation at a young age experience a much greater increase in breast cancer risk than women who are exposed in their 30s or 40s.

The authors acknowledge that their study involved only a small number of breast cancer patients and did not have the power to examine the role of other breast cancer risk factors, such as use of hormone replacement therapy and pregnancies before and after treatment for Hodgkin's disease. More insight may come from a large, ongoing study coordinated by the National Cancer Institute, the authors say.

In an accompanying editorial, Dan L. Longo, M.D., of the National Institute on Aging in Baltimore, Md., says that although the current study is small, the findings are robust. "These data make a strong argument for radiation therapy as the initiator and physiologic sex hormones as promoters of secondary breast cancer," he says.

However, he cautions that the findings are based on older chemotherapy regimens and that newer, less toxic forms of chemotherapy have virtually no effect on the onset of menopause and therefore may not be associated with a decrease in risk of breast cancer.

Longo adds that even low doses of radiation substantially increase the risk of breast cancer and points out that 80% to 85% of patients with Hodgkin's disease can be cured without radiation treatment. He argues that radiation therapy should be reserved for patients with large masses or those who do not respond completely to chemotherapy.
-end-
Contact: Netherlands Cancer Institute
Department of Communications
31-20-5122850
l.kuipers@nki.nl.

Van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van't Veer MB, Noordijk EM, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003;95:971-80.

Editorial: Longo D. Radiation therapy in the treatment of Hodgkin's disease--Do you see what I see? J Natl Cancer Inst 2003;95:928-9.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Journal of the National Cancer Institute

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.